Dermatoprotective activity of a combination of enoxifol with rexod in a reduced form the blood circulation in the skin in diabetes mellitus and hypercholesterinemia

Abstract

Experiments in rats showed that the 9-diethylaminoethyl-2-(3,4-dioxyphenyl)-imidazo-[1,2-a]-benzimidazole dihydrobromide with the provisional name of enoxifol (0.94 – 15 mg/kg), rexod (recombinant human superoxide dismutase; 0.002 mg/kg) and especially their combination in intravenous administration in a reduced blood circulation in the skin against the background of
the normoglycemia and hyperglycemia induced by experimental (alloxanic) diabetes mellitus complicated by exogenous hypercholesterinemia have a pronounced dose-dependent dermatoprotective effect, which may be due to the activation of energy processes and increase the reserve capacity of the antioxidant support network and normalization of carbohydrate and lipid metabolism. A combination of enoxifol with alprostadil in normoglycemia increases significantly dermatoprotective activity of alprostadil and exceeds the activity of the combination of enoxifol with rexod. Under the conditions of normoxia and hypoxia, induced by sodium cyanide, and uncouple of oxidative phosphorylation, induced by 2,4-dinitrophenol, a combination of enoxifol with rexod, increases the viability of cultured osteoblasts and fibroblasts. Enoxifol (7.5 mg/kg, intravenously) has anti-inflammatory effect in edema induced by carrageenan, histamine, serotonin and Freund's complete adjuvant. Enoxifol (7.5 mg/kg, intravenously), rexod (0.02 mg/kg, intravenously) and especially its combination have a pronounced antiulcer action on steroid ulcers of a stomach, enoxifol activity compare poorly of the sea buckthorn oil (10 ml/kg intraperitoneally); the combination of enoximone with rexod much is much superior as enoxifol, rexod and sea buckthorn oil taken from separately.